| J9271 | Injection, pembrolizumab, 1 mg | 5,600 | $40 | $246.4K |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase‑fihj | 4,500 | $40 | $171K |
| J0897 | Injection, denosumab, 1 mg | 2,760 | $20 | $52.4K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 190 | $90 | $16.6K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 210 | $60 | $12.3K |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 140 | $80 | $10.4K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 110 | $90 | $10.2K |
| 99212 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a straightforward level of medical decision making,… | 250 | $40 | $9.2K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 4,500 | $1 | $9K |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 30 | $340 | $8.4K |